The 2019 novel coronavirus (2019-nCoV) infection caused clusters of severe respiratory
illness similar to SARS and was associated with ICU admission and high mortality. There is no
confirmed antivirus therapy for people infected 2019-nCoV, most of them should receive
supportive care to help relieve symptoms. This clinical trial is to evaluate the effect of
Fuzheng Huayu tablet on lung inflammation in intensive patients with novel coronavirus
pneumonia and reduce the progressive rate to critical type.
Phase:
Phase 4
Details
Lead Sponsor:
ShuGuang Hospital
Collaborators:
Hubei Hospital of Traditional Chinese Medicine Jingmen No.1 People's Hospital